Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 17;25(16):8971.
doi: 10.3390/ijms25168971.

Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models

Rayanne Poletti Guimarães  1 , Maria Clara Souza de Resende  1 , Miguel Mesquita Tavares  1 , Caio Belardinelli de Azevedo  1 , Miguel Cesar Merino Ruiz  1   2 , Márcia Renata Mortari  1
Affiliations
Review

Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models

Rayanne Poletti Guimarães et al. Int J Mol Sci. .

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease globally. Current drugs only alleviate symptoms without halting disease progression, making rodent models essential for researching new therapies and understanding the disease better. However, selecting the right model is challenging due to the numerous models and protocols available. Key factors in model selection include construct, face, and predictive validity. Construct validity ensures the model replicates pathological changes seen in human PD, focusing on dopaminergic neurodegeneration and a-synuclein aggregation. Face validity ensures the model's symptoms mirror those in humans, primarily reproducing motor and non-motor symptoms. Predictive validity assesses if treatment responses in animals will reflect those in humans, typically involving classical pharmacotherapies and surgical procedures. This review highlights the primary characteristics of PD and how these characteristics are validated experimentally according to the three criteria. Additionally, it serves as a valuable tool for researchers in selecting the most appropriate animal model based on established validation criteria.

Keywords: Parkinson’s disease; animal models; construct validity; experimental medicine; face validity; predictive validity; translational research.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Construct validity in rodent models of Parkinson’s disease: key pathological hallmarks simulated in models, primary induction methods, and techniques used for induction.
Figure 2
Figure 2
Main symptoms of Parkinson’s disease, primary rodent models capable of simulating it, and tests used for face validity analysis.
Figure 3
Figure 3
Main treatments used in the predictive validation of rodent models of Parkinson’s disease.
See this image and copyright information in PMC

References

    1. Tysnes O.-B., Storstein A. Epidemiology of Parkinson’s disease. J. Neural Transm. 2017;124:901–905. doi: 10.1007/s00702-017-1686-y. - DOI - PubMed
    1. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 1988;51:745–752. doi: 10.1136/jnnp.51.6.745. - DOI - PMC - PubMed
    1. Ramesh S., Arachchige A.S.P.M. Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci. 2023;10:200–231. doi: 10.3934/Neuroscience.2023017. - DOI - PMC - PubMed
    1. Sarkar S., Raymick J., Imam S. Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives. Int. J. Mol. Sci. 2016;17:904. doi: 10.3390/ijms17060904. - DOI - PMC - PubMed
    1. Kouli A., Torsney K.M., Kuan W.-L. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; Brisbane, Australia: 2018. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis; pp. 3–26. - PubMed

Substances

LinkOut - more resources